Objective. To analyse therapeutic management of eosinophilic fasciitis (EF).
Introduction
In 1975, Shulman described eosinophilic fasciitis (EF) as a rare connective tissue disease characterized by a symmetrical and painful swelling with a progressive induration of the skin and soft tissues [1, 2] . In the absence of international diagnostic criteria, diagnosis of EF is now based on the association of characteristic skin or subcutaneous abnormalities and a thickened fascia with an inflammatory infiltration, mostly composed of lymphocytes and eosinophils [3, 4] . Peripheral eosinophilia is present in 6393% of patients, although not mandatory for EF diagnosis [3, 4] .
Therapeutic management of EF is one of the most significant challenges, as the clinical, biological and pathological features are well defined. Mainstay therapy is based on steroids with a partial or complete response in just over 60% of patients [4] . Use of immunosuppressive drugs (AZA, CYC, MTX, ciclosporin and, more recently, anti-TNF-a and rituximab) is not codified, and is mostly justified by failure of, or dependence on, high doses of CSs [411] .
The aim of our study was to highlight new insights into EF therapeutic management. We set up a retrospective study of 34 adult patients with biopsy-proven EF and analysed their therapeutic management, including treatment modalities, response and associated prognostic factors.
Methods

Study design
We retrospectively reviewed medical charts of adult patients treated or referred to our University Hospital for EF between January 1992 and May 2010. EF diagnosis was based on suggestive clinical and laboratory findings and a biopsy-proven fascia involvement [1, 4, 5] . No patient had an L-tryptophane-associated eosinophiliamyalgia syndrome. Informed consent was obtained for each patient.
Data collection and variables of interest
Collected data included demographic parameters, presence, type and distribution of cutaneous, articular and muscular involvement. Morphoea was diagnosed clinically when skin sclerosis was noticed and histologically when a dermal fibrosis was noticed [4, 12] . Subcutis sclerosis was diagnosed clinically when a deep subcutis induration was present without involvement of the superficial skin. Baseline biological data included eosinophil count, creatinine phosphokinase (CPK), CRP, serum gammaglobulin level and, when available, immunological markers: ANCA, ANA, anti-ENA antibodies. Peripheral hypereosinophilia was defined by an absolute number of peripheral eosinophils >500/mm 3 [3] .
Skinfasciomuscular biopsy
All patients underwent a full thickness skin to muscle biopsy following a standard protocol and the pathological analyses were performed in the same laboratory by M.T. or D.O. Diagnosis of EF was assessed by the evidence of a fasciitis with a thickened fascia and inflammatory infiltrates composed of lymphocytes and/or eosinophils [4] .
Treatment
Data regarding treatment regimen, clinical and biological responses were collected. Recorded treatments included oral steroids, i.v. methylprednisolone pulses (MPPs), immunosuppressive drugs (ISDs) (MTX, AZA) and immunomodulatory drugs (HCQ, colchicine). Prescribed treatment was the responsibility of the patient's physician.
Treatment response definitions
Response to treatment was defined as: (i) failure (patients with persistent active physical signs and symptoms); (ii) remission (patients with disability, i.e. persistent joint contractures, tendon retraction or subcutis sclerosis); and (iii) complete remission (free of symptoms at end of follow-up and resolution of physical findings). A poor outcome was defined as failure or presence of a disability.
A complete laboratory response was defined as the normalization of peripheral eosinophil count.
Statistical analysis
Continuous variables were compared using the t-test or the KruskalWallis test, and categorical variables using Fisher's exact or 2 tests as appropriate. A stepwise multiple logistic regression analysis was used to assess independent associations based on the results of univariate analyses (P < 0.1). Rates of event-free survival (ISD, poor outcome) over time were plotted by KaplanMeier's method and compared using the log-rank test. A Cox proportional hazards multiple regression model was used to evaluate the relative risk (RR) associated with the introduction of an ISD. All tests were two-tailed and a P 4 0.05 was considered statistically significant. All statistical analyses were performed using the MedCalc software version 11.1.1.0 (Mariakerke, Belgium).
Results
Patients characteristics and clinical manifestations
Thirty-four patients were included ( 
Patients with a poor outcome
Ten patients experienced a poor outcome (four patients with failure and six patients with remission with disability). They tended to have a longer diagnosis time delay [8.1 (5.3) months vs 5 (3) months, P = 0.07], with a higher proportion of patients with a diagnosis time delay >6 months (60 vs 18%; P = 0.037) ( Table 1 ). They more frequently received an ISD (90 vs 23%; P < 0.01) and inversely they tended to less frequently receive MPPs (20 vs 59%; P = 0.06). After multivariate analysis, two baseline parameters remained independently associated with patients having a poor outcome: a diagnosis delay >6 months (OR = 14.7; 95% CI 1.5, 147.7; P = 0.023) and the absence of MPPs at treatment initiation (OR = 12.9; 95% CI 1.7, 142.7; P = 0.037).
Features of patients with morphoea-like lesions
Fifteen (44%) patients had a clinical and/or histological morphoea at diagnosis. Seven (47%) patients received MPPs before oral steroids and 10 (67%) patients received an ISD, which was MTX in all cases, as a second-line therapy. Complete remission was achieved in nine (60%) patients, remission with disability in three (20%) patients and failure in three (20%) patients. Compared with patients without morphoea-like lesions (n = 19), patients with morphoea-like lesions were more likely to have a subcutis sclerosis (100 vs 53%; P = 0.002), a groove sign (73 vs 37%; P = 0.045), a histological fascia fibrosis (67 vs 21%, P = 0.013) and higher CRP level [29.6 (19.6) mg/l vs 12.6 (12.5) mg/l; P = 0.02). They more frequently received an ISD (67 vs 23%; P = 0.03), mostly MTX.
Discussion
Since the first description by Shulman in 1975, up to 300 cases of EF have been reported [1, 35] . However, although clinical, biological and histological features of EF patients are well defined, therapeutic management remains unclear. We therefore designed this study and focused on therapeutic management and its associated factors. Our patients received CSs at initiation as a first-line therapy and MPPs were given to 47% of patients at treatment initiation. A second-line therapy, based on the use of an ISD, usually MTX, was necessary for 44% of patients, due to an unsatisfactory response to steroid treatment. Taking into account all treatments, complete remission was achieved in 69% of patients. A poor outcome was present in one-third of patients and was associated with two independent factors: a diagnosis time delay >6 months (OR = 14.7; P = 0.023) and the lack of MPPs at treatment initiation (OR = 12.9; P = 0.037). Interest in early treatment after symptom onset has already been reported by Endo et al. [3] . The use of MPPs was associated with a better outcome and allowed a significant decrease of the risk of requiring of an ISD treatment as a second-line therapy.
Another main point of our study was the focus on patients presenting morphoea-like lesions. It is well established that morphoea can reveal or complicate EF [3, 4, 13, 14] . Clinical morphoea were present in 41% of patients, higher than the 19 and 28% reported in previous studies [3, 4] . This difference is probably explained by the presence of senior dermatologists in our department (C.F., S.B.). A systematic review of previous reports suggested that presence of morphoea-like skin lesions could be a risk factor for residual fibrosis [3] . We identified frequent use of ISDs in patients with morphoea-like lesions, probably because those lesions are more difficult to cure. In our study, MTX was used in most patients, based on previous reports of disabling morphoea [15, 16] . Good results of MTX treatment combined with MPPs have also been reported in paediatric studies [15, 16] . This regimen warrants further study to assess whether early treatment with an ISD improves the outcome in these often recalcitrant patients.
Some biases including a retrospective design and the lack of standardized criteria for the evaluation of treatment response might have impacted the results of the present study. We also agree that our results are not generalizable and might simply reflect the treatment preferences of a single centre. This being said, our study leads to practical conclusions regarding EF management and might help to set up a mandatory prospective and multicentre study.
Rheumatology key messages
. CS treatment remains the standard therapy for EF. . MPPs might allow a better outcome and a lower need of ISDs for EF. . An ISD, usually MTX, might be useful in patients with morphoea-like lesions.
